Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $11 | $22 | $7 |
| % Growth | -75.9% | -48.1% | 198.9% | – |
| Cost of Goods Sold | $74 | $2 | $0 | $0 |
| Gross Profit | -$71 | $9 | $22 | $7 |
| % Margin | -2,580.7% | 81.8% | 100% | 100% |
| R&D Expenses | $74 | $78 | $80 | $72 |
| G&A Expenses | $17 | $18 | $16 | $16 |
| SG&A Expenses | $17 | $18 | $16 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$70 | -$2 | $0 | $0 |
| Operating Expenses | $21 | $94 | $97 | $88 |
| Operating Income | -$93 | -$85 | -$74 | -$81 |
| % Margin | -3,347.4% | -736.8% | -336.8% | -1,092.2% |
| Other Income/Exp. Net | $10 | $8 | $9 | $10 |
| Pre-Tax Income | -$82 | -$77 | -$66 | -$71 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$82 | -$77 | -$66 | -$71 |
| % Margin | -2,973% | -667.6% | -296.7% | -956.9% |
| EPS | -0.94 | -0.95 | -0.82 | -0.88 |
| % Growth | 1.1% | -15.9% | 6.8% | – |
| EPS Diluted | -0.94 | -0.95 | -0.82 | -0.88 |
| Weighted Avg Shares Out | 87 | 80 | 80 | 80 |
| Weighted Avg Shares Out Dil | 87 | 80 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $8 | $9 | $10 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $2 | $2 | $2 |
| EBITDA | -$79 | -$74 | -$63 | -$69 |
| % Margin | -2,870% | -648.5% | -287.2% | -929.2% |